EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease

Hiroaki Harada iD, Hirofumi Shoda iD, Haruka Tsuchiya iD, Makoto Misaki iD, Takayuki Sawada iD, Keishi Fujio iD

Rheumatology International · 08.03.2024 · 44 (5) · 961-971

DOI: 10.1007/s00296-024-05551-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rheumatology International, online erschienen am 08.03.2024. Verfasst von Hiroaki Harada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. haradamd@gm…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Dermatomyositis, Lung Diseases, Interstitial, Azetidines. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge. We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients. We reviewed 6 patients with anti-MDA5-DM-ILD who had been treated with tofacitinib at our institution. Five of the patients survived, although discontinuation of tofacitinib due to complications was frequently observed. In addition, a literature search of patients with anti-MDA5-DM-ILD who were treated with JAK inhibitors yielded 21 articles involving 79 cases. All patients except one were treated with tofacitinib, and the survival rate was 75.9%. Although not statistically confirmed, the deceased patients tended to be older and had higher ferritin levels. A total of 92 complications were observed, 11 of which resulted in JAK inhibitor discontinuation. Cytomegalovirus reactivation comprised a substantial percentage of all complications and of those patients who required JAK inhibitor discontinuation. Five cases with fatal infective complications were also observed. While tofacitinib has been proposed to be a therapeutic option for anti-MDA5-DM-ILD, other JAK inhibitors, including baricitinib, are a treatment option. Further investigation is warranted to optimize treatment of anti-MDA5-DM-ILD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsDermatomyositisLung Diseases, InterstitialAzetidinesPurinesPyrazolesSulfonamidesHumansAutoantibodiesRetrospective StudiesPrognosisInterferon-Induced Helicase, IFIH1

Stichwörter der Autor:innen

Anti-MDA5 antibody-positive dermatomyositisBaricitinibInterstitial lung diseaseJAK inhibitorsTofacitinib

Substanzen

Janus Kinase InhibitorsbaricitinibAutoantibodiesInterferon-Induced Helicase, IFIH1AzetidinesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. haradamd@gmail.com.
  • Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

ORCID-Profile: Hiroaki Harada, Hirofumi Shoda, Haruka Tsuchiya, Makoto Misaki, Takayuki Sawada, Keishi Fujio

Zitieren

APA

Harada, H., Shoda, H., Tsuchiya, H., Misaki, M., Sawada, T., & Fujio, K. (2024). Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatology International, 44(5), 961-971. https://doi.org/10.1007/s00296-024-05551-2

Vancouver

Harada H, Shoda H, Tsuchiya H, Misaki M, Sawada T, Fujio K. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatology International. 2024;44(5):961-971. doi:10.1007/s00296-024-05551-2

BibTeX
@article{Harada2024,
  author = {Harada, Hiroaki and Shoda, Hirofumi and Tsuchiya, Haruka and Misaki, Makoto and Sawada, Takayuki and Fujio, Keishi},
  title = {Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease},
  journal = {Rheumatology International},
  year = {2024},
  volume = {44},
  number = {5},
  pages = {961--971},
  doi = {10.1007/s00296-024-05551-2}
}
Kostenlos starten →